Search





Search





Markets
/
Stocks
/
nasdaq-crbu
/

Caribou Biosciences Inc

CRBU

Add to Watchlist

2.140USD

0.0000.00%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

212.25MMarket Cap

LossP/E TTM



Caribou Biosciences Inc

2.140

0.0000.00%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Caribou Biosciences Inc

Currency: USD Updated: 2026-05-15

Key Insights

Caribou Biosciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.12.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Caribou Biosciences Inc's Score

Industry at a Glance

Industry Ranking

120 / 382

Overall Ranking

246 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Caribou Biosciences Inc Highlights

StrengthsRisks

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.16M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 11.16M.

Fairly Valued

The company’s latest PE is -1.51, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 35.96M shares, decreasing 40.06% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 83.50K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

12.125

Target Price

+466.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Caribou Biosciences Inc is 5.83, ranking 308 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 2.40M, representing a year-over-year increase of 1.87%, while its net profit experienced a year-over-year increase of 37.27%.

Score

Industry at a Glance

Previous score

5.83

Change



Financials

5.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Caribou Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Caribou Biosciences Inc is 7.73, ranking 82 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.51, which is -70.07% below the recent high of -0.45 and -295.29% above the recent low of -5.97.

Score

Industry at a Glance

Previous score

7.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Caribou Biosciences Inc is 8.67, ranking 70 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 32.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

12.125

Target Price

+466.59%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Caribou Biosciences Inc

CRBU

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Caribou Biosciences Inc is 6.87, ranking 135 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.41 and the support level at 1.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.85

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.024

Buy

RSI(14)

58.257

Neutral

STOCH(KDJ)(9,3,3)

62.848

Neutral

ATR(14)

0.135

High Vlolatility

CCI(14)

114.635

Buy

Williams %R

36.735

Buy

TRIX(12,20)

-0.049

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.092

Buy

MA10

2.007

Buy

MA20

2.062

Buy

MA50

1.989

Buy

MA100

1.818

Buy

MA200

1.931

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Caribou Biosciences Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 36.25%, representing a quarter-over-quarter decrease of 49.07%. The largest institutional shareholder is James Simons, holding a total of 2.59M shares, representing 2.61% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Pfizer Inc

4.69M

Haurwitz (Rachel E. Ph.D.)

3.59M

+4.41%

Kynam Capital Management LP

2.50M

-18.40%

Two Sigma Investments, LP

2.14M

+6.21%

BlackRock Institutional Trust Company, N.A.

2.06M

+42.19%

ACATIS Investment Kapitalverwaltungsgesellschaft GmbH

2.00M

SELECTRA Management Company S.A.

1.65M

Renaissance Technologies LLC

Star Investors

1.64M

+110.12%

abrdn Inc.

1.39M

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Caribou Biosciences Inc is 2.27, ranking 229 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Caribou Biosciences Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.